Portola Pharmaceuticals (PTLA) to Release Quarterly Earnings on Wednesday

Portola Pharmaceuticals (NASDAQ:PTLA) is set to announce its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($1.33) per share for the quarter.

Portola Pharmaceuticals (PTLA) opened at $45.10 on Wednesday. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a 12 month low of $28.43 and a 12 month high of $67.10. The stock has a market cap of $2,940.00, a price-to-earnings ratio of -10.44 and a beta of 1.18.

In other news, Director Henry Ward Wolff sold 12,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Several equities analysts have issued reports on PTLA shares. Oppenheimer restated a “buy” rating and issued a $80.00 price objective on shares of Portola Pharmaceuticals in a research note on Tuesday, November 7th. Goldman Sachs Group started coverage on shares of Portola Pharmaceuticals in a research note on Friday, December 1st. They issued a “buy” rating and a $75.00 price objective for the company. BidaskClub downgraded shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 7th. Citigroup restated a “buy” rating and issued a $74.00 price objective on shares of Portola Pharmaceuticals in a research note on Thursday, December 28th. Finally, William Blair restated a “buy” rating on shares of Portola Pharmaceuticals in a research note on Monday, January 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $70.65.

TRADEMARK VIOLATION NOTICE: “Portola Pharmaceuticals (PTLA) to Release Quarterly Earnings on Wednesday” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/portola-pharmaceuticals-ptla-to-release-quarterly-earnings-on-wednesday.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply